Evidence of differential mycobacterial growth and modulation of mycobactericidal property by glucoaminylmuramyl dipeptide in murine macrophages

Annals of the New York Academy of Sciences

Volumn 832, Issue , 1997, Pages 117-129

  Venkataprasad, Nandagopal ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSAMINYLMURAMYL DIPEPTIDE; SUPEROXIDE;

ANIMAL CELL; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; IMMUNOMODULATION; MACROPHAGE; MOUSE; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERITONEUM MACROPHAGE; SPLEEN CELL;

ACTINOBACTERIA (CLASS); ANIMALIA; BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MURINAE; MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; UNCULTURED ACTINOMYCETE;

EID: 0031574430     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1997.tb46241.x     Document Type: Conference Paper

References (24)

1. ELLOUZ, F., A. ADAM, R. CIORBARU & E. LEDERER. 1974. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59: 1317-1325.
2. FLECK, J., M. MOCK, F. TYTGAT, C. NAUCIEL & R. MINCEK. 1974. Adjuvant activity in delayed hypersensitivity of the peptidic part of bacterial peptidoglycans. Nature 250: 517-518.
3. CHEDID, L., M. PARANT, F. PARANT, P. LEFRANCIER, J. CHOAY & E. LEDERER. 1977. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuamyl-L-alanyl-D-isoglutamine) and several analogs. Proc. Natl. Acad. Sci. USA 74: 2089-2093.
4. BOMFORD, R., M. STAPLETON, S. WINSOR, A. MCKNIGHT & T. ANDRONOVA. 1992. The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS Res. Human Retroviruses 8: 1765-1771.
5. BOMFORD, R. 1992. Adjuvants for viral vaccines. Med. Virol. 2: 169-174.
6. KHAITOV, R. M., B. V PINEGIN, A. A. BUTAKOV & T. M. ANDRONOVA. 1994. Immunotherapy of infectious postoperative complications with glucosaminylmuramyl dipeptide. In Immunotherapy of Infections. N. Masihi, Ed.: 205-211. Marcel Dekker, Inc. New York.
7. JOHNSTON, R. B., B. B. KEELE, H. P. MISHRA, J. E. LEHMEYER, L. S. WEBB, R. L. BAEHNER & K. V. RAJAGOPALAN. 1975. The role of Superoxide anion generation in phagocytic bactericidal activity: Studies with normal and chronic granulomatous disease leukocytes. J. Clin. Invest. 55: 1357-1372.
8. DRATH, D. B. & M. L. KARNVOSKY. 1975. Superoxide production by phagocytic leukocytes. J. Exp. Med. 141: 257-262.
9. CUMMINGS, N. C., M. J. PABST & R. B. JOHNSTON. 1980. Activation of macrophages for enhanced release of Superoxide anion and greater killing of Candida albicans by injection of muramyl dipeptide. J. Exp. Med. 152: 1659-1669.
10. EDWARDS, C. K., H. B. HEDEGAARD, A. ZLOTNIK, P. R. GANGADHARAM, R. B. JOHNSTON & M. J. PABST. 1986. Chronic infection due to Mycobacterium intracellulare in mice: Association with macrophage release of prostaglandin E2 and reversal by injection of indomethacin, muramyl dipeptide or interferon-γ. J. Immunol. 136: 1820-1827.
11. GARRETT, K. C., H. B. RICHERSON & G. W. HUNNINGHAKE. 1984. Mechanisms of granuloma formation. Am. Rev. Respir. Dis. 130: 477-483.
12. HUNNINGHAKE, G. W., K. C. GARRETT, H. B. RICHERSON, J. C. PANTONE, P. A. WARD, S. I. RENNARD, P. B. BITTERMAN & R. G. CRYSTAL. 1984. Pathogenesis of the granulomatous lung diseases. Am. Rev. Respir. Dis. 130: 476-477.
13. NATHAN, C., N. NOGUEIRA, C. JUANGBHANICH, J. ELLIS & Z. COHN. 1979. Activation of macrophages in vivo and in vitro: Correlation between hydrogen peroxide release and killing of Trypanosoma cnizi. J. Exp. Med. 149: 1056-1068.
14. MURRAY, H. W., C. NATHAN & Z. A. COHN. 1980. Macrophage oxygen-dependent antimicrobial activity: IV Role of endogenous scavengers of oxygen intermediates. J. Exp. Med. 152: 1610-1624.
15. MURRAY, H. W. 1981. Susceptibility of Leishmania to oxygen intermediates and killing by normal macrophages. J. Exp. Med. 153: 1302-1314.
16. CATTERALL, J. R., C. M. BLACK, J. P. LEVENTHAL, N. W. RIZK, J. S. WACHTEL & J. S. REMINGTON. 1987. Nonoxidative microbicidal activity in normal human alveolar and peritoneal macrophages. Infect. Immun. 55: 1635-1640.
17. INOUE, S., S. ITAGAKI & E AMANO. 1995. Intracellular killing of Listeria monocytogenes in the J774.1 macrophage-like cell line and the lipopolysaccharide (LPS)-resistant mutant LPS1916 cell line defective in the generation of reactive oxygen intermediates after LPS treatment. Infect. Immun. 63: 1876-1886.
18. PABST, M. J. & R. B. JOHNSTON. 1980. Increased production of Superoxide anion by macrophages exposed in vitro to muramyl dipeptide or lipopolysaccharide. J. Exp. Med. 151: 101-114.
19. MURRAY, H. W. 1981. Interaction of Leishmania with a macrophage cell line: Correlation between intracellular killing and the generation of oxygen intermediates. J. Exp. Med. 153: 1690-1695.
20. VENKATAPRASAD, N., P. LEDGER & J. IVANYI. 1997. The effect of glucosaminylmuramyl dipeptide (GMDP) injection to mice on the course of tuberculosis infection and in vitro Superoxide anion production. Int. Arch. Allergy Immunol. 114: 23-29.
21. PROCTOR, R. A. 1979. Endotoxin in vitro interactions with human neutrophils: Depression of chemiluminescence, oxygen consumption, Superoxide production and killing. Infect. Immun. 25: 912-921.
22. O'REILLY, T. & O. ZAK. 1992. Enhancement of the effectiveness of antimicrobial therapy by muramyl peptide immunomodulators. Clin. Infect. Dis. 14: 1100-1109.
23. KAYDALOV, A. A., Y. N. UTKIN, T. M. ANDRONOVA, V. I. TSETLIN & V T. IVANOV. 1989. Muramyl peptides bind specifically to rat brain membranes. FEES Lett. 248: 78-82.
24. ZIDEK, Z. 1992. Differences in proinflammatory activity of several immunomodulatory derivatives of muramyl dipeptide (MDP) with special reference to the mechanism of the MDP effects. Agents Actions 36: 136-145.